Shigella Vaccines Market Growth Accelerated by Rising Morbidity Rates

 


Shigella vaccines have gained popularity owing to the growing prevalence of Shigella infection globally. Shigella bacteria causes shigellosis, which is a gastrointestinal infection commonly known as bacillary dysentery. Shigella infection leads to abdominal pain, diarrhea with possible traces of blood or mucus, fever, nausea, and vomiting. Shigella vaccines help prevent Shigella infection and associated complications.

The global Shigella Vaccines Market is estimated to be valued at US$ 574.20 mn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Rising morbidity rates have accelerated the growth of the Shigella vaccines market over the forecast period. According to the World Health Organization (WHO), Shigella causes an estimated 80-165 million cases and causes around 69,000 deaths annually worldwide, with majority of deaths occurring in low-income countries and among children under five years of age. In the U.S., Shigella causes approximately 500,000 cases annually. Growing disease prevalence has boosted awareness regarding the need for effective prevention of Shigella infection, thereby driving the demand for Shigella vaccines over the forecast period.

Segment Analysis
The global Shigella vaccines market is dominated by the multivalent Shigella vaccines segment. These vaccines provide protection against multiple Shigella serotypes that are responsible for shigellosis such as Shigella flexneri and Shigella sonnei. These multivalent Shigella vaccines are more effective as they offer wider protection compared to monovalent Shigella vaccines that protect against only one serotype. Therefore, the multivalent Shigella vaccines segment is currently dominating the market.

Key Takeaways
The global Shigella vaccines market is expected to witness high growth over the forecast period of 2023-2030.

Regional analysis: North America currently dominates the market due to high research activities for shigellosis vaccines and presence of major players. However, Asia Pacific region is expected to witness fastest growth due to increasing incidence of shigellosis infections in developing Asian countries.
Asia Pacific region is poised to witness fastest growth in the Shigella vaccines market led by China, India, and other Southeast Asian countries. This is attributed to rising healthcare awareness and improving healthcare infrastructure in emerging economies. Additionally, high prevalence of shigellosis infections especially in densely populated areas creates significant demand for preventive vaccines.

Key players operating in the Shigella vaccines market are MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., Novartis (Novartis Vaccines Institute for Global Health), and GlaxoSmithKline plc. MSD Wellcome Trust Hilleman Laboratories has an ongoing phase III trial of their multivalent Shigella conjugate vaccine in Bangladesh to evaluate its efficacy.

Comments

Popular posts from this blog

Neuroendocrine Cancer is the fastest growing segment fueling the growth of Pituitary Cancer Market

Enhancing Patient Care and Comfort: The Evolution of Hospital Beds

Dry Eye Disease Market is Estimated to Witness High Growth Owing to Rising Awareness About Disease Management